Coherus BioSciences (CHRS) Reports Q3 Loss of $1.79
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.20 -1.64%
Revenue Growth %: +37.8%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: +37.8%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.79), versus ($6.23) reported last year. Revenue for the quarter came in at $16.1 million, versus $500 thousand reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS sees a negative catalyst ahead for Nike: Here’s what to watch
- Surgery Partners sells Idaho Falls facilities to Intermountain Health for $797M
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
